Shares of Novartis AG (VTX:NOVN) have earned an average recommendation of “Hold” from the fourteen ratings firms that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is CHF 88.64.
Several equities analysts have commented on NOVN shares. Jefferies Financial Group raised their price objective on Nice to $166.00 and gave the company a “buy” rating in a research report on Thursday, May 16th. Kepler Capital Markets set a €160.00 ($186.05) price objective on Pfeiffer Vacuum Technology and gave the company a “buy” rating in a research report on Tuesday, May 21st. JPMorgan Chase & Co. set a €50.00 ($58.14) price objective on Brenntag and gave the company a “buy” rating in a research report on Tuesday. UBS Group reissued a “neutral” rating on shares of CAIXABANK/ADR in a research report on Thursday. Finally, Goldman Sachs Group started coverage on Enbridge in a research report on Thursday. They set a “neutral” rating for the company.
Novartis has a fifty-two week low of CHF 72.45 and a fifty-two week high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Further Reading: How Important is Technical Analysis of Stocks
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.